Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Hye Sook | - |
dc.contributor.author | Kim, Bum Jun | - |
dc.contributor.author | Jee, Hee-Jung | - |
dc.contributor.author | Ryu, Min-Hee | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Rha, Sun Young | - |
dc.contributor.author | Kim, Jong Gwang | - |
dc.contributor.author | Bae, Woo Kyun | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, In-Ho | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Oh, So Yeon | - |
dc.contributor.author | Kim, Hyeong Su | - |
dc.contributor.author | Byun, Ji-Hye | - |
dc.contributor.author | Kim, Dong Sook | - |
dc.contributor.author | Suh, Young Ju | - |
dc.contributor.author | An, Hyonggin | - |
dc.contributor.author | Zang, Dae Young | - |
dc.date.accessioned | 2022-02-22T03:42:31Z | - |
dc.date.available | 2022-02-22T03:42:31Z | - |
dc.date.created | 2022-02-07 | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136458 | - |
dc.description.abstract | Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study cohorts focused on ramucirumab plus paclitaxel in gastric cancer are limited. Methods: The study population comprised all patients with gastric or GEJ cancer who received ramucirumab plus paclitaxel in South Korea between 1 May 2018 and 31 December 2018. We included patients with advanced gastric or GEJ adenocarcinoma and disease progression after first-line platinum and fluoropyrimidine-containing combination chemotherapy. Results: In total, 1063 patients were included in the present study. The objective response rate and disease control rate were 15.1% and 57.7%, respectively. The median progression-free survival was 4.03months (95% confidence interval, 3.80-4.27) and the median overall survival was 10.03months (95% confidence interval, 9.33-10.73). Grade 3 or higher treatment-related adverse events with incidence of 5% were neutropenia (35.1%) and anemia (10.5%). Based on multivariable analysis, overall survival was negatively associated with Eastern Cooperative Oncology Group performance status 2, weight loss 10% in the previous 3months, GEJ of primary tumor, poor or unknown histologic grade, number of metastatic sites 3, presence of peritoneal metastasis, no prior gastrectomy, and time to second-line since first-line treatment <6months. Conclusion: Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject | RANDOMIZED CLINICAL-TRIAL | - |
dc.subject | PHASE-III | - |
dc.subject | 1ST-LINE THERAPY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | OPEN-LABEL | - |
dc.subject | CANCER | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | RAINBOW | - |
dc.subject | COMBINATION | - |
dc.subject | EAST | - |
dc.title | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | An, Hyonggin | - |
dc.identifier.doi | 10.1177/17588359211042812 | - |
dc.identifier.scopusid | 2-s2.0-85115063816 | - |
dc.identifier.wosid | 000697412800001 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, v.13 | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - |
dc.citation.title | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - |
dc.citation.volume | 13 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | EAST | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | RAINBOW | - |
dc.subject.keywordPlus | RANDOMIZED CLINICAL-TRIAL | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | ramucirumab | - |
dc.subject.keywordAuthor | real-world data | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.